Emma Börgeson
UNIVERSITETSLEKTOR/BITRÄDANDE
Department of Molecular and ClinicalAbout Emma Börgeson
Assistant Professor, Principal Investigator
Emma Börgeson is an assistant professor in the Department of Molecular and Clinical Medicine. She joined the faculty as a tenure-track fellow in the Wallenberg Centre for Molecular and Translational Medicine (WCMTM) at Gothenburg University. Dr. Börgeson leads a small but dedicated translational research team, investigating the therapeutic potential of immunomodulation in obesity-related cardiometabolic pathophysiology.
After completing her PhD in medicine at University College Dublin in 2011, Dr Börgeson received a Marie Curie fellowship from the European Commission to do a three-year post doc at the University of San Diego (UCSD). There, she investigated the therapeutic potential of immunomodulation in models of obesity, with a particular focus on chronic kidney disease. Her current research focus is to identify the anti-inflammatory mechanisms that control obesity-related cardiometabolic disease and to translate these findings to human pathophysiology.
Emma Börgeson has received numerous honors and awards.
Honors & Awards
- Junior Investigator Award, International Conference on Phospholipase A2 and Lipid Mediators, San Diego. 2016
- Emerging Leaders in Nutritional Sciences, Experimental Biology, San Diego. 2016
- Nominated for the Hasselblad Foundation Award for women scientists, Sweden. 2015
- Highlighted poster, Bioactive Lipids in Inflammation & Diseases, Puerto Rico. 2013
- Nominated for Roche National Researcher of the Year, Ireland. 2013
- Honorary Directors Prize due to special distinction, UCD Conway festival, Ireland. 2013
- Best moderated poster, Diabetes & Vascular biology, UCD Conway festival, Ireland. 2013
- Best scientific presentation, Irish Society of Nephrology, Ireland. 2013
- Outstanding junior career progression, ERA-EDTA ‘Molecular Targets in Renal Disease’ Symposia, Germany. 2011
Main Research
We are a translational research team, investigating the underlying disease mechanisms of obesity and cardiometabolic disease, with a special interest in inflammatory resolution.
Inflammation is a key driver of obesity-induced cardiometabolic pathophysiology and consists of two phases: an initial acute phase followed by a resolving phase. The latter is actively regulated by specialized pro-resolving lipid mediators (SPMs). Lipoxins are one group of SPMs that act through defined receptors to promote resolution of inflammation.
The overall aim of our research is to investigate and harness the therapeutic potential of lipoxins. Our studies suggest that treatment with lipoxins attenuates obesity-induced adipose inflammation and subsequent development of systemic disease (Börgeson et al, Cell Metabolism, 2015). We are currently investigating the underlying mechanisms that mediate this protection, and whether our results from preclinical models can be translated to human pathophysiology.
We combine experimental studies with clinical basic research to address our hypotheses in a translational manner. We use ex vivo culture of tissue biopsies, which provide valuable “proof-of-principle” evidence to correlate our experimental data with human physiology. This translational approach requires state-of-the art experimental and clinical facilities, as well as a broad network of expertise, made possible via our collaborators. For more information on our research, please visit Borgeson lab.
Group Members
- Matúš Soták, PhD: Postdoctoral Fellow
- Meenu Rohini Rajan, PhD: Postdoctoral Fellow
- Fredrik Barrenäs, PhD: Senior Research Associate
- Madison Clark: Undergraduate Researcher
- Emelie Shehadeh: Undergraduate Researcher
Key Publications
- Meenu Rohin Rajan, Matus Sotak, Fredrik Barrenäs, Tong Shen, Kamil Borkowski, Nicholas J Ashton, Christina Biörserud, Tomas L Lindahl, Sofia Ramström, Michael Schöll et al. Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Scientific reports Oct 28;9(1):15385. (2019) doi: 10.1038/s41598-019-51673-0.
Key original papers
- Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K. AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia. 60(4):729-739 (2017).
- Börgeson E, Johnsson A, Lee Y.S., Till A, Syed H, Ali-Shah, Guiry P, Dalli D, Colas R, Serhan CN, Godson C, Sharma K. Lipoxin A4 attenuates obesity-induced adipose inflammation, liver and kidney disease. Cell Metabolism. 7;22(1):125-37 (2015).
- Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. Lipoxin A4 attenuates adipose inflammation. FASEB Journal. 26(10):4287-94 (2012).
- Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB Journal. 25(9):2967-79. (2011).
- Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T. Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. Infection and Immunity 79(4):1489-97. (2011).
Key review papers
- Börgeson E. The role of lipoxins in cardiometabolic physiology and disease. Cardiovascular Endocrinology Journal, October 28, doi: 10.1097/XCE.0000000000000068. (2015).
- Börgeson E, Sharma K. Obesity, immunomodulation and chronic kidney disease. Current Opinion in Pharmacol. 13(4):618-24. (2013).
- Börgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Frontiers in Immunology, 18;3:318. (2012).
For more information, please visit: Börgesonlab.org
-
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and
serum.
Meenu Rohin Rajan, Matus Sotak, Fredrik Barrenäs, Tong Shen, Kamil Borkowski, Nicholas J. Ashton, Christina Biörserud, Tomas L Lindahl, Sofia Ramström, Michael Schöll, Per Lindahl, Oliver Fiehn, John W Newman, Rosie Perkins, Ville Wallenius, Stephan Lange, Emma Börgeson
Scientific reports - 2019-01-01 -
miR-486 is modulated by stretch and increases ventricular
growth
Stephan Lange, I. Banerjee, K. Carrion, R. Serrano, L. Habich, R. Kameny, L. Lengenfelder, N. Dalton, R. Meili, Emma Börgeson, K. Peterson, M. Ricci, J. Lincoln, M. Ghassemian, J. Fineman, J. C. del Alamo, V. Nigam
Jci Insight - 2019-01-01 -
Obesity-induced changes in lipid mediators persist after weight
loss
A. Hernandez-Carretero, N. Weber, M. R. La Frano, W. Ying, Juan Lantero Rodriguez, D. D. Sears, Ville Wallenius, Emma Börgeson, J. W. Newman, O. Osborn
International Journal of Obesity - 2018-01-01 -
AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of
adiponectin.
Emma Börgeson, Ville Wallenius, Gulam H Syed, Manjula Darshi, Christina Biörserud, Malin Ragnmark Ek, Per Björklund, Marianne Quiding-Järbrink, Lars Fändriks, Catherine Godson, Kumar Sharma, Juan Lantero Rodriguez
Diabetologia - 2017-01-01 -
The role of lipoxins in cardiometabolic physiology and
disease
Emma Börgeson
Cardiovascular Endocrinology - 2016-01-01 -
The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in
mice.
Linlin Zhong, Yun Ding, Gautam Bandyopadhyay, Jo Waaler, Emma Börgeson, Susan Smith, Mingchen Zhang, Susan A Phillips, Sepi Mahooti, Sushil K Mahata, Jianhua Shao, Stefan Krauss, Nai-Wen Chi
Diabetologia - 2016-01-01 -
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney
Disease.
Emma Börgeson, Andrew M F Johnson, Yun Sok Lee, Andreas Till, Gulam Hussain Syed, Syed Tasadaque Ali-Shah, Patrick J Guiry, Jesmond Dalli, Romain A Colas, Charles N Serhan, Kumar Sharma, Catherine Godson
Cell metabolism - 2015-01-01 -
Obesity, immunomodulation and chronic kidney
disease.
Emma Börgeson, Kumar Sharma
Current opinion in pharmacology - 2013-01-01 -
IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic
responses.
James B Corcoran, Sarah McCarthy, Brenda Griffin, Andrew Gaffney, Una Bhreathnach, Emma Börgeson, Fionnuala B Hickey, Neil G Docherty, Debra F Higgins, Fiona Furlong, Finian Martin, Catherine Godson, Madeline Murphy
Biochimica et biophysica acta - 2013-01-01 -
Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing
TGFβR1.
Emma Börgeson, Eoin P Brennan, Karen A Nolan, Oisín S Gough, Caitríona M McEvoy, Neil G Docherty, Debra F Higgins, Madeline Murphy, Denise M Sadlier, Syed Tasadaque Ali-Shah, Patrick J Guiry, David A Savage, Alexander P Maxwell, Finian Martin, Catherine Godson
Journal of the American Society of Nephrology : JASN - 2013-01-01 -
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal
complications.
Emma Börgeson, Catherine Godson
Frontiers in immunology - 2012-01-01 -
Lipoxin A4 attenuates adipose
inflammation.
Emma Börgeson, Fiona C McGillicuddy, Karen A Harford, Niamh Corrigan, Debra F Higgins, Paola Maderna, Helen M Roche, Catherine Godson
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 2012-01-01 -
Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal
fibrosis.
Emma Börgeson, Neil G Docherty, Madeline Murphy, Karen Rodgers, Aidan Ryan, Tim P O'Sullivan, Patrick J Guiry, Roel Goldschmeding, Debra F Higgins, Catherine Godson
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 2011-01-01 -
Lipoxin A₄ inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b
expression.
Emma Börgeson, Johanna Lönn, Ida Bergström, Veronika Patcha Brodin, Sofia Ramström, Fariba Nayeri, Eva Särndahl, Torbjörn Bengtsson
Infection and immunity - 2011-01-01 -
Molecular circuits of resolution in renal
disease.
Emma Börgeson, Catherine Godson
TheScientificWorldJournal - 2010-01-01